Latest From Fudan University
Innovative drug makers are resorting to patient assistance and commercial insurance programs for their high-priced therapies in China. Pfizer is test-driving a new approach for its smoking cessation drug.
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June 2014.
China’s NDRC launched a national engineering lab for therapeutic vaccines on June 7 at Fudan University, with the first planned effort of research a therapeutic vaccine for Hepatitis B.
AstraZeneca has signed a collaboration agreement with Chinese research institution Tianjin Medical University to co-explore novel targets against cardiac fibrosis. The agreement builds on a string of such academic collaborations in the country focused on growing chronic diseases.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.